D
Dermira
Development-stage biotech company focused on developing and commercializing innovative new therapies in dermatology
About Dermira
Dermira, a subsidiary of Eli Lilly and Company, operates in the dermatology sector, focusing on developing and commercializing treatments for chronic skin conditions such as hyperhidrosis (excessive sweating) and atopic dermatitis (eczema). The company primarily serves healthcare professionals and patients in the United States. Dermira's business model revolves around the research, development, and marketing of its proprietary products, including FDA-approved treatments like glycopyrronium cloth for hyperhidrosis and lebrikizumab for atopic dermatitis, which is currently in clinical trials. Revenue is generated through product sales, partnerships, and licensing agreements. The company emphasizes compliance with FDA regulations and provides extensive medical information and support to healthcare professionals.
Source: Dealroom company dataAt a glance
- Founded
- 2010
- Headquarters
- Redwood City, United States
- Listing
- IPO 2014
- Sector
- Biotech & Life Sciences
- Power Law
- Colt$25–100M revenue
Latest news
Press, funding announcements and product moves mentioning Dermira.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later5 investors entered at this stage
Apple Tree Partners
UCB
Aisling Capital
Rock Springs Capital
Sabby Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Dermira on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Dermira on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.